Drug
Isoquercitrin clinical trials
Also written IQC-950AN and quercetin-3-O-glucoside.
- studies test it
- 11
- open now
- 2
- in phase 3
- 2
- first study started
- 2015
Keep track of what changes. Save the isoquercitrin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Other names
Combined with it in one product
Studies by the year they started
11 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 3 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 9
- Phase 3
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 9
Jeffrey Zwicker, MD (2) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Tulane University (1) · Memorial Sloan Kettering Cancer Center (1) · Quercis Pharma AG (1) · AB Science (1) · Nepal Health Research Council (1) · Consorzio Oncotech (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses isoquercitrin is read from its arms, and is right about nine times in ten.
Testing it · 11
- A Study of Isoquercetin in People With Ovarian CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07303894Written as Isoquercetin
- The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic CancerRecruitingPhase 3Quercis Pharma AGNCT06861088Written as Kinisoquin™
- Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of COVID-19WithdrawnPhase 2Institut de Recherches Cliniques de MontrealNCT04536090Written as Isoquercetin (IQC-950AN)
- Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell DiseaseCompletedPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT04514510Written as Isoquercetin
- Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19Status unknownPhase 2AB ScienceNCT04622865Written as Isoquercetin
- Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) TrialCompletedPhase 2Tulane UniversityNCT02552888Written as Isoquercetin
- Cancer Associated Thrombosis and Isoquercetin (CATIQ)CompletedPhase 2/3Jeffrey Zwicker, MDNCT02195232Written as Isoquercetin
- Study to Investigate the Clinical Efficacy of Isoquercetin in Patients With COVID-19Status unknownPhase 2Nepal Health Research CouncilNCT04733651Written as Isoquercetin
- Isoquercetin in Sickle Cell AnemiaWithdrawnPhase 2Jeffrey Zwicker, MDNCT04474626Written as Isoquercetin
- Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II TrialStatus unknownPhase 1/2Consorzio OncotechNCT02446795Written as Isoquercetin
- Impact of isoQUercetin and Aspirin on Platelet FunctionWithdrawnNot applicableUniversity of ReadingNCT02866448Written as Isoquercetin
Codes
What other systems call isoquercitrin · ClinicalTrials.gg INT002652
- MeSH (NLM) C016527isoquercitrinOne source NLM
- UNII (FDA) 0YX10VRV6JISOQUERCITRINConfirmed FDA, NLM, Wikidata
- Wikidata Q27103621isoquercitrinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C99879IsoquercitrinOne source FDA
- DrugBank DB16403One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C016527 | isoquercitrin | One source NLM |
| UNII (FDA) | 0YX10VRV6J | ISOQUERCITRIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27103621 | isoquercitrin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C99879 | Isoquercitrin | One source FDA |
| DrugBank | DB16403 | — | One source Wikidata |
Also registered as isoquercetin (UNII 6HN2PC637T).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.